New York, USA, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rich Insights into the Glaucoma Clinical Trial Analysis Featuring 70+ Companies and Therapies | DelveInsight
The number of clinical trials in glaucoma research has increased significantly over the past few years. With future innovative drug development where the aspect of personalized medicines is considered, an increasing phase transition success rate in glaucoma clinical trials could be seen. Pharmaceutical companies have begun looking development of sustained-release (SR) implants, which can routinely self-administer the active ingredient into the patients’ eyes.
DelveInsight’s 'Glaucoma Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline glaucoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the glaucoma pipeline domain.
Key Takeaways from the Glaucoma Pipeline Report
- DelveInsight’s glaucoma pipeline report depicts a robust space with 60+ active players working to develop 70+ pipeline therapies for glaucoma treatment.
- Key glaucoma companies such as Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision, HK inno.N, Avirmax Inc., and others are evaluating new drugs for glaucoma to improve the treatment landscape.
- Promising glaucoma pipeline therapies in various stages of development include QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP – 716, BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa, ENV515-3, ANX007, T-4032, Bimatoprost PF, BTQ 1901 / BTQ 1902, PA5108, PRO-122, PHP-201, DE-126, POLAT-001, TRS01, ST266, RTC-1119, INM-088, IN-A010, and others.
- In August 2022, Alcon agreed to acquire Aerie Pharmaceuticals for about $770 million, betting its sprawling commercial presence can boost the uptake of the biotechnology company’s two glaucoma drugs. The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline. Alcon will pay $15.25 for each share of Aerie, a 37% premium to the stock’s closing price.
- In March 2022, Oculis S.A. and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. The agreement supports Oculis’s mission to become a global ophthalmology leader bringing breakthrough innovations to the top three segments of the market: retina, dry eye and glaucoma.
- In February 2022, Ocular Therapeutix presented interim Phase I data for OTX-TIC, highlighting the product candidate’s ability to cause a clinically meaningful decrease in intraocular pressure (IOP) for six months or longer with a single implant in many subjects while preserving corneal health. The Company is actively enrolling its US-based Phase II prospective, multi-center, randomized, controlled clinical trial evaluating the safety, tolerability, and efficacy of OTX-TIC for the treatment of patients with primary open-angle glaucoma or ocular hypertension.
- AM008 is a bioresorbable intracameral implant containing micronized travoprost that is injected into the anterior chamber of the eye with a target duration of drug delivery of four to six months. AM008 is in development for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. In a Phase I clinical trial, all cohorts experienced a mean reduction in IOP from a baseline of 7-11 mmHg with the onset of action as early as two days after insertion. Many subjects across the four cohorts demonstrated durability of activity of 6 months or longer with a single implant. Overall, no serious ocular adverse events were noted. AM008 is designed to directly address compliance issues by delivering travoprost over the course of several months with a single implant.
- NCX 470 is a novel, potential best-in-class, nitric oxide (NO)-donating prostaglandin analog eye drop, designed to release bimatoprost and NO into the eye to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. NCX 470 is currently in two multi-regional Phase III clinical trials. NCX 470 is covered worldwide until 2029 under a composition of matter patent with potential extension up to 5 years in the US and EU and a formulation patent until 2039 in the US, EU, Japan and China.
- Sun Pharma Advanced Research Company (SPARC) reported positive top-line results from its Phase III trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension. The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1 percent dosed three times a day.
Request a sample and discover the recent advances in glaucoma treatment drugs @ Glaucoma Pipeline Report
The glaucoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage glaucoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the glaucoma clinical trial landscape.
Glaucoma Overview
Glaucoma is a group of eye diseases that damage the optic nerve. The optic nerve transports images from the retina, a specialized light-sensitive tissue, to the brain, allowing us to see. Eye pressure contributes to the damage of the sensitive nerve fibers of the optic nerve in glaucoma. The exact glaucoma causes are still not known. Glaucoma symptoms and signs differ depending on the type and stage of the disease.
Glaucoma treatment for glaucoma is determined by the kind and severity of each condition. Glaucoma, in general, cannot be cured, although it can be managed.
Find out more about glaucoma treatment drugs @ Drugs for Glaucoma Treatment
A snapshot of the Glaucoma Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| NCX 470 | Nicox | Phase III | Nitric oxide donors | Ophthalmic |
| TRS01 | Tarsier Pharma | Phase III | Carbonic anhydrase inhibitors; Prostaglandin F2 alpha agonists | Ophthalmic |
| STN1012600 | Santen Pharmaceutical | Phase III | Prostaglandin E EP3 receptor agonists; Prostaglandin F2 alpha agonists | Ophthalmic |
| QLS-101 | Qlaris Bio, Inc. | Phase II | KATP channel modulators | Ophthalmic |
| VVN-539 | VivaVision Biotech | Phase II | Nitric oxide donors; Rho-associated kinase inhibitors | Ophthalmic |
| TO-O-1001 | Theratocular Biotek Co. | Phase I/II | Rho-associated kinase inhibitors | Ophthalmic |
| AGN-193408 | AbbVie | Phase I/II | NA | Ophthalmic |
| JV-GL1 | JeniVision | Phase I/II | Protein kinase inhibitors | Ophthalmic |
| Visomitin | Mitotech | Phase I | Antioxidants; Electron transport chain complex protein modulators | Ophthalmic |
| ONL1204 | ONL Therapeutics | Phase I | Apoptosis inhibitors; CD95 antigen inhibitors; Fas ligand protein modulators | Ophthalmic |
| MAN-01 | Q BioMed | Preclinical | TIE-2 receptor modulators | Ophthalmic |
Learn more about the emerging glaucoma pipeline therapies @ Glaucoma Clinical Trials
Glaucoma Therapeutics Assessment
The glaucoma pipeline report proffers an integral view of glaucoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Glaucoma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Inhalation, Parenteral, Intranasal, Intravenous, Oral, Subcutaneous
- Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine
- Therapeutics Assessment By Mechanism of Action: KATP channel modulators, Nitric oxide donors, Protein kinase inhibitors, Carbonic anhydrase inhibitors, Prostaglandin F2 alpha agonists, Antioxidants, Electron transport chain complex protein modulators, TIE-2 receptor modulators, Cannabinoid receptor agonists
- Key Glaucoma Companies: Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision, HK inno.N, Avirmax Inc., and others.
- Key Glaucoma Pipeline Therapies: QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP – 716, BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa, ENV515-3, ANX007, T-4032, Bimatoprost PF, BTQ 1901 / BTQ 1902, PA5108, PRO-122, PHP-201, DE-126, POLAT-001, TRS01, ST266, RTC-1119, INM-088, IN-A010, and others.
Dive deep into rich insights for new drugs for glaucoma treatment, visit @ Glaucoma Medications
Table of Contents
| 1. | Glaucoma Pipeline Report Introduction |
| 2. | Glaucoma Pipeline Report Executive Summary |
| 3. | Glaucoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Glaucoma Clinical Trial Therapeutics |
| 6. | Glaucoma Pipeline: Late Stage Products (Pre-registration) |
| 7. | Glaucoma Pipeline: Late Stage Products (Phase III) |
| 7.1 | NCX 470: Nicox |
| 8. | Glaucoma Pipeline: Mid Stage Products (Phase II) |
| 8.1 | QLS-101: Qlaris Bio, Inc. |
| 9. | Glaucoma Pipeline: Early Stage Products (Phase I) |
| 9.1 | Visomitin: Mitotech |
| 10. | Glaucoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Glaucoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Glaucoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the glaucoma pipeline therapeutics, reach out @ Glaucoma Treatment Drugs
Related Reports
Glaucoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucoma companies including Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, among others.
Glaucoma Epidemiology Forecast
Glaucoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted glaucoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Open Angle Glaucoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key open angle glaucoma companies, including AbbVie, PolyActiva, SALVAT, among others.
Open Angle Glaucoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key open angle glaucoma companies, including AbbVie, PolyActiva, SALVAT, among others.
Primary Open Angle Glaucoma Market
Primary Open Angle Glaucoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key primary open angle glaucoma companies including Occular Therapeutics, Aerpio Therapeutics, Aerie Pharmaceuticals, among others.
Primary Open Angle Glaucoma Pipeline
Primary Open Angle Glaucoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary open angle glaucoma companies, including Occular Therapeutics, Aerpio Therapeutics, Aerie Pharmaceuticals, among others.
Other Trending Reports
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
